Skip to content
Invokana(canagliflozin)
Invokamet, Invokana, Vokanamet (canagliflozin) is a small molecule pharmaceutical. Canagliflozin was first approved as Invokana on 2013-03-29. It is used to treat type 2 diabetes mellitus in the USA. It has been approved in Europe to treat type 2 diabetes mellitus. The pharmaceutical is active against sodium/glucose cotransporter 2. In addition, it is known to target sodium/glucose cotransporter 1.
Download report
Favorite
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
nutritional and metabolic diseasesD009750
endocrine system diseasesD004700
Trade Name
FDA
EMA
Invokana
Combinations
Invokamet
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Canagliflozin
Tradename
Company
Number
Date
Products
INVOKANAJohnson & JohnsonN-204042 RX2013-03-29
2 products, RLD, RS
Canagliflozin
+
Metformin hydrochloride
Tradename
Company
Number
Date
Products
INVOKAMETJohnson & JohnsonN-204353 RX2014-08-08
4 products, RLD, RS
INVOKAMET XRJohnson & JohnsonN-205879 RX2016-09-20
4 products, RLD, RS
Labels
FDA
EMA
Brand Name
Status
Last Update
invokamet invokamet xrNew Drug Application2022-10-20
invokanaNew Drug Application2022-12-15
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
type 2 diabetes mellitusEFO_0001360D003924E11
Agency Specific
FDA
EMA
No data
Patent Expiration
Patent
Expires
Flag
FDA Information
Canagliflozin, Invokana, Janssen Pharms
106176682031-05-11DPU-493, U-2441, U-2632, U-2794, U-2795, U-2796, U-2797, U-2798, U-2799
79435822029-02-26DS, DPU-493, U-2441, U-2632
85132022027-12-03DS, DPU-493, U-2441, U-2632
79437882027-07-14DS, DP
82222192025-04-11U-493, U-2441, U-2632
Canagliflozin / Metformin Hydrochloride, Invokamet, Janssen Pharms
115768942030-07-06DP
87854032024-07-30DP
ATC Codes
A: Alimentary tract and metabolism drugs
A10: Drugs used in diabetes
A10B: Blood glucose lowering drugs, excl. insulins
A10BD: Combinations of oral blood glucose lowering drugs
A10BD16: Metformin and canagliflozin
A10BK: Sodium-glucose co-transporter 2 (sglt2) inhibitors
A10BK02: Canagliflozin
HCPCS
No data
Clinical
Clinical Trials
128 clinical trials
View more details
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Type 2 diabetes mellitusD003924EFO_0001360E111162019862
ObesityD009765EFO_0001073E66.9235
Cardiovascular diseasesD002318EFO_0000319I981214
Diabetes mellitusD003920EFO_0000400E08-E13123
OverweightD050177E66.3112
Systolic heart failureD054143EFO_1001207I50.2011
HyperuricemiaD03346111
GoutD006073EFO_0004274M1011
AlbuminuriaD000419EFO_0004285R80.911
HypertensionD006973EFO_0000537I1011
Show 1 more
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Heart failureD006333EFO_0003144I50213
Diabetic nephropathiesD003928EFO_0000401123
Renal insufficiencyD051437HP_0000083N19112
Risk factorsD012307EFO_000391911
Coronary artery diseaseD003324I25.1111
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Type 1 diabetes mellitusD003922EFO_0001359E10112
Breast neoplasmsD001943EFO_0003869C50122
Colorectal neoplasmsD015179111
Endometrial neoplasmsD016889EFO_0004230111
Head and neck neoplasmsD006258111
Lung neoplasmsD008175C34.90111
Polycystic ovary syndromeD011085EFO_0000660E28.2111
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Healthy volunteers/patients4444
Therapeutic equivalencyD01381011
Plasma volumeD01095311
Hepatic insufficiencyD04855011
Indications Without Phase
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
HypoglycemiaD007003HP_0001943E16.211
Prediabetic stateD011236EFO_1001121R73.0311
HivD006678O98.711
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameCANAGLIFLOZIN
INNcanagliflozin
Description
Canagliflozin is a C-glycosyl compound that is used (in its hemihydrate form) for treatment of type II diabetes via inhibition of sodium-glucose transport protein subtype 2. It has a role as a hypoglycemic agent and a sodium-glucose transport protein subtype 2 inhibitor. It is a C-glycosyl compound, a member of thiophenes and an organofluorine compound.
Classification
Small molecule
Drug classphlorozin derivatives, phenolic glycosides
Image (chem structure or protein)
Structure (InChI/SMILES or Protein Sequence)
Cc1ccc([C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)cc1Cc1ccc(-c2ccc(F)cc2)s1.O
Identifiers
PDB
CAS-ID842133-18-0
RxCUI1546031
ChEMBL IDCHEMBL4594217
ChEBI ID
PubChem CID24812758
DrugBankDB08907
UNII ID6S49DGR869 (ChemIDplus, GSRS)
Target
Agency Approved
SLC5A2
SLC5A2
Organism
Homo sapiens
Gene name
SLC5A2
Gene synonyms
SGLT2
NCBI Gene ID
Protein name
sodium/glucose cotransporter 2
Protein synonyms
Low affinity sodium-glucose cotransporter, Na(+)/glucose cotransporter 2, solute carrier family 5 (sodium/glucose cotransporter), member 2, solute carrier family 5 (sodium/glucose transporter), member 2, Solute carrier family 5 member 2
Uniprot ID
Mouse ortholog
Slc5a2 (246787)
sodium/glucose cotransporter 2 (Q923I7)
Alternate
SLC5A1
SLC5A1
Organism
Homo sapiens
Gene name
SLC5A1
Gene synonyms
NAGT, SGLT1
NCBI Gene ID
Protein name
sodium/glucose cotransporter 1
Protein synonyms
High affinity sodium-glucose cotransporter, Na+/glucose cotransporter 1, solute carrier family 5 (sodium/glucose cotransporter), member 1, Solute carrier family 5 member 1
Uniprot ID
Mouse ortholog
Slc5a1 (20537)
sodium/glucose cotransporter 1 (Q8C3K6)
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Additional graphs summarizing 6,641 documents
View more details
Safety
Black-box Warning
Black-box warning for: Invokamet invokamet xr
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
15,291 adverse events reported
View more details